The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program
Related Resources
All Resources
post
Accelerating Drug Development: Regulatory Strategies for Fast-Track and Breakthrough Therapy Designations
Read More
post
Navigating the Evolution from ICH Q2(R1) to ICH Q2(R2) and Implementation of ICH Q14 in Biopharmaceutical Method Validation
Read More
post
Regulatory Affairs Compliance Strategies
Read More
post
The FDA NDA Review Timeline Explained: A Step-by-Step Breakdown
Read More
Let's move from science to success.
Let’s Talk